5’-guanosine monophosphate (GMP)-producing microorganism and method for producing 5’-guanosine monophosphate using the same
Patent Information
- Application Number
- MYPI2025003445
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-28
- Filing Date
- 2024-02-06
- Publication Date
- 2024-08-28
AI Technical Summary
Current methods for producing 5'-guanosine monophosphate (GMP) are complex and inefficient, requiring suppression of GMP decomposition by microorganisms and high conversion ability from 5'-xanthosine monophosphate (XMP), with a need for new strains with high GMP conversion ability and low degradation rate for enhanced production.
The Corynebacterium ammoniagenes CJG0497 strain, deposited under accession number KCCM13320P, is identified for its high GMP conversion ability and low decomposition rate, enabling high-yield production of 5'-guanic acid through culturing in a specific medium and recovery of the product.
This strain effectively produces 5'-guanic acid in high yield, addressing the inefficiencies of existing production methods by enhancing conversion ability and reducing degradation, thus facilitating industrial-scale production.
Abstract
Description
5'-guanine acid producing strain and method for producing 5'-guanine acid using the same
[0001] The present application relates to a method for producing 5'-guanic acid, comprising the step of culturing the strain of Corynebacterium ammoniagenes CJG0497 deposited under accession number KCCM13320P; a composition for producing 5'-guanic acid, comprising the strain, a culture of the strain, a fermented product of the strain, or a combination of two or more thereof; and a use of the strain for producing 5'-guanic acid.
[0002]
[0003] 5'-Guanosine monophosphate (GMP) is an intermediate in nucleic acid biosynthesis and plays a vital physiological role in both plants and animals. It is also widely used in food, pharmaceuticals, and various other medical applications. It is one of the nucleic acid-based seasonings that is gaining attention as a palatable seasoning, particularly due to its significant flavor enhancement effect when used with monosodium glutamate (MSG).
[0004] GMP manufacturing methods include (1) decomposing yeast RNA using microbial enzymes or chemically; (2) directly producing nucleotides through microorganisms in a medium containing sugars, nitrogen sources, and phosphate sources; and (3) chemically or enzymatically converting intermediates in nucleotide synthesis. Currently, a combined manufacturing method combining fermentation, chemical synthesis, and enzymatic conversion is widely used industrially.
[0005] This complex manufacturing method consists of a fermentation process that uses microorganisms to produce 5'-xanthosine monophosphate (XMP), an intermediate product of the purine nucleotide biosynthesis metabolic chain, and an enzymatic reaction process that converts the fermentation products into GMP. Microorganisms that produce XMP and microorganisms that can convert XMP into GMP are used. Therefore, in order to produce GMP efficiently, the decomposition of GMP by microorganisms involved in GMP production must be suppressed, and in particular, the microorganisms introduced in the enzymatic reaction process must have a high complex ability to convert XMP into GMP.
[0006] Accordingly, various studies are being conducted to develop high-efficiency production microorganisms and fermentation process technologies. For example, target-substance-specific approaches, such as increasing the expression of genes encoding enzymes involved in XMP or GMP biosynthesis or removing genes unnecessary for biosynthesis, are primarily being utilized (EP 3722430 A1, US 2020-0347346 A1).
[0007] However, research on new strains with high GMP conversion ability and low GMP degradation rate is still needed to effectively increase 5'-guanine acid production.
[0008]
[0009] The present inventors completed the present application by confirming that the Corynebacterium ammoniagenes CJG0497 strain deposited under accession number KCCM13320P has a high GMP conversion ability and a low GMP degradation rate, thereby being able to produce 5'-guanine acid in high yield.
[0010]
[0011] One aspect of the present application provides a strain of Corynebacterium ammoniagenes CJG0497 deposited under accession number KCCM13320P.
[0012] In one specific example, the strain may have the ability to produce 5'-guanine acid.
[0013] In another specific example, the strain may have a converting ability to convert 5'-xanthrylic acid into 5'-guanine acid.
[0014] Another aspect of the present application provides a method for producing 5'-guanine acid, comprising the step of culturing the Corynebacterium ammoniagenes CJG0497 strain deposited under accession number KCCM13320P in a medium.
[0015] In one specific example, the method may further comprise a step of recovering 5'-guanine acid from the cultured strain, a culture of the strain, a fermentation product of the strain, or the culture medium.
[0016] Another aspect of the present application provides a composition for producing 5'-guanine acid, comprising the strain Corynebacterium ammoniagenes CJG0497 deposited under accession number KCCM13320P, a culture of the strain, a fermentation product of the strain, or a combination of two or more thereof.
[0017] Another aspect of the present application provides a use of the strain Corynebacterium ammoniagenes CJG0497, deposited under accession number KCCM13320P, for producing 5'-guanine acid.
[0018]
[0019] The Corynebacterium ammoniagenes CJG0497 strain deposited under the accession number KCCM13320P of this application can produce 5'-guanine acid in high yield by having high GMP conversion ability and low GMP degradation rate, and thus can be usefully utilized in the industrial production of 5'-guanine acid.
[0020]
[0021] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.
[0022] Furthermore, those skilled in the art will recognize or be able to ascertain, using only routine experimentation, numerous equivalents to the specific embodiments of the present application described herein. Furthermore, such equivalents are intended to be encompassed by this application.
[0023] As used in the specification and appended claims of this application, the singular articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Unless the context clearly dictates otherwise, the singular terms include the plural and the plural terms include the singular. In the specification and appended claims of this application, unless the context clearly dictates otherwise, the use of "or" is intended to include "and / or."
[0024]
[0025] In this application, the term "about" may be used before a specific numerical value. As used herein, the term "about" encompasses not only the exact number described after the term, but also a range that is or is nearly that number. Whether a number is or is nearly the specific number described can be determined based on the context in which it is presented. For example, the term "about" may refer to a range of -10% to +10% of a numerical value. In another example, the term "about" may refer to a range of -5% to +5% of a given numerical value. However, this is not a limitation.
[0026] In this application, the term "comprising" means the presence of a feature, step, or component described below, and does not exclude the presence or addition of one or more features, steps, or components. The components or features described below "comprising" in this application may be essential or mandatory, but in some embodiments, other optional or non-essential components or features may be further included.
[0027]
[0028] One aspect of the present application provides a strain of Corynebacterium ammoniagenes CJG0497 deposited under accession number KCCM13320P.
[0029] The strain of the present application may refer to a mutant strain obtained by mutating a parent strain. Specifically, it may include all strains capable of producing the desired 5'-guanine acid by mutating the Corynebacterium ammoniagenes ATCC6872 strain (currently referred to as the Corynebacterium stationanis ATCC6872 strain).
[0030] In this regard, mutagenesis of microorganisms can be performed by various means widely known in the art, and can utilize either physical or chemical mutagenesis methods. For example, gamma radiation and ultraviolet rays can be used as physical mutagens suitable for the present invention, but are not limited thereto. In addition, N-methyl-N'-nitro-N-nitrosoguanidine (NTG), diepoxybutane, ethyl methane sulfonate, mustard compounds, hydrazine, and nitrous acid can be used as chemical mutagens, but are not limited thereto.
[0031] During mutagenesis, the parent strain is exposed to a mutagen under conditions that leave a certain size of viable cells. These conditions vary depending on the type of mutagen and depend on the amount of mutations the mutagen induces in the viable cells with a certain killing rate. For example, in the case of gamma radiation, the killing rate can leave approximately 0.00001% to 20% of the starting population. In the case of NTG, the killing rate can leave approximately 10% to 50% of the starting population. Mutagenesis by nitrite can leave approximately 0.01% to 0.1% of the starting population, but is not limited thereto.
[0032]
[0033] In one specific example, the strain may have the ability to produce 5'-guanine acid.
[0034] In another specific example, the strain may have a converting ability to convert 5'-xanthrylic acid into 5'-guanine acid.
[0035]
[0036] In this application, the term "5'-guanosine monophosphate (GMP)" refers to a nucleotide having a structure in which a phosphate group forms an ester bond to the ribose portion of a guanosine molecule. The 5'-guanosine monophosphate (GMP) can be used interchangeably. The GMP can be synthesized by adding an ammonia molecule to 5'-xanthosine monophosphate (XMP) by 5'-guanosine monophosphate (GMP synthase). A method for producing GMP from XMP and / or a means used in the method can be selected from known techniques.
[0037] In this application, the term "5'-xanthosine monophosphate (XMP)" refers to a nucleotide dehydrogenated from IMP. The 5'-xanthosine monophosphate may be used interchangeably with XMP. The XMP may be synthesized from IMP by 5'-inosine-5'-monophosphate dehydrogenase.
[0038]
[0039] The Corynebacterium ammoniagenes CJG0497 strain deposited under the accession number KCCM13320P of this application can produce 5'-guanine acid in high yield by having high GMP conversion ability and low GMP degradation rate, and thus can be usefully utilized in the industrial production of 5'-guanine acid.
[0040]
[0041] As a specific example, the strain of the present application may be a strain with increased 5'-guanine acid production ability compared to the parent strain, but is not limited thereto. For example, the parent strain, which is the target strain for comparing whether the 5'-guanine acid production ability is increased, may be Corynebacterium ammoniagenes ATCC6872, but is not limited thereto.
[0042] As another specific example, the strain of the present application may be a strain having an increased ability to convert 5'-xanthrylic acid into 5'-guanine acid compared to the parent strain, but is not limited thereto.
[0043] As another specific example, the strain of the present application may be a strain having a reduced rate of 5'-guanine acid degradation compared to the parent strain, but is not limited thereto.
[0044]
[0045] Meanwhile, the Corynebacterium ammoniagenes CJG0497 strain deposited under the accession number KCCM13320P, which has 5'-guanine acid production ability of the present application, may include the strain itself, a strain having improved 5'-guanine acid production ability by increasing or decreasing the activity of a gene related to the 5'-guanine acid production mechanism, or a strain having improved 5'-guanine acid production ability by introducing or increasing the activity of an external gene.
[0046]
[0047] Another aspect of the present application provides a method for producing 5'-guanine acid, comprising the step of culturing the Corynebacterium ammoniagenes CJG0497 strain deposited under the accession number KCCM13320P of the present application in a medium.
[0048] In this application, the term "cultivation" refers to growing the strain of this application under appropriately controlled environmental conditions. The cultivation process of this application can be performed using any suitable medium and culture conditions known in the art. This cultivation process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the cultivation may be batch, continuous, and / or fed-batch, but is not limited thereto.
[0049] In this application, the term "medium" refers to a material containing nutrients as its main component necessary for culturing the strain of this application, and supplies nutrients and growth factors, including water, which is essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the strain of this application may be any medium used for culturing a conventional strain without particular limitation, but the strain of this application may be cultured under aerobic conditions while controlling temperature, pH, etc. in a conventional medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin. For example, a culture medium for a strain of the genus Corynebacterium can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].
[0050] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0051] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.
[0052] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.
[0053] In addition, during the cultivation of the strain of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, in order to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or in order to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.
[0054] In the culture of the present application, the culture temperature can be maintained at 27 to 37°C, specifically 30 to 33°C, and the culture can be performed for about 20 to 120 hours, but is not limited thereto.
[0055] In the present application, the term "culture" means a culture solution, concentrated culture solution, dried product of culture solution, culture filtrate, concentrated culture filtrate, or dried product of culture filtrate obtained by culturing a specific strain in a culture medium, wherein the culture solution means that it contains a specific strain, and the culture filtrate means that it does not substantially contain a specific strain (here, substantially means excluding a specific strain separated by filtration or the like, but does not mean that the strain is completely excluded from the filtrate). The culture is not limited in its formulation, and may be, for example, a liquid, an emulsion, or a solid. Specifically, for the purpose of the present application, the culture may contain 5'-guanidine acid.
[0056] In this application, the term "fermentation" refers to a process in which a strain uses its own enzymes to decompose organic matter, but not to a putrefaction reaction. While fermentation and putrefaction occur through similar processes, if the resulting decomposition produces useful substances, it is called fermentation. If the resulting decomposition produces odorous or harmful substances, it is called putrefaction.
[0057] In the present application, the method for obtaining a fermented product from the strain is not particularly limited, and can be obtained according to a method commonly used in the relevant technical field or a similar field.
[0058] In the present application, the term "fermentation" includes all kinds of materials including a fermentation product produced from the strain, such as not only the fermented material itself, but also a culture medium of the strain in which the strain and the culture coexist, a fermentation product obtained by filtering the strain from the culture medium, a fermentation product obtained by sterilizing the strain from the culture medium and filtering it, an extract obtained by extracting the fermentation product or a culture medium containing it, a diluted solution obtained by diluting the fermentation product or its extract, a concentrate obtained by drying the fermentation product or its extract, a lysate obtained by capturing and crushing the cells of the strain, etc.
[0059] In the method of the present application, any culture conditions and methods known in the art can be used for culturing the strain. Those skilled in the art can easily adjust and use this culture process depending on the selected strain.
[0060] 5'-guanine acid produced by the culture of the present invention may be secreted into the medium or remain within the cells.
[0061]
[0062] In one specific example, the method for producing 5'-guanine acid of the present application may further include a step of preparing a strain of the present application, a step of preparing a medium for culturing the strain, or a combination thereof (in any order), for example, prior to the culturing step.
[0063] The method for producing 5'-guanine acid of the present application may further include a step of recovering the target substance, specifically 5'-guanine acid, from the cultured strain, a culture of the strain, a fermented product of the strain, or the culture medium. The recovering step may be additionally included after the culturing step.
[0064] The above recovery may be performed by collecting the target 5'-guanidine acid using a suitable method known in the art, depending on the culture method of the strain of the present application, such as a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallizing protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and the target substance, specifically 5'-guanidine acid, may be recovered from the medium or strain using a suitable method known in the art.
[0065] Additionally, the method for producing 5'-guanine acid of the present application may additionally include a purification step. The purification may be performed using any suitable method known in the art. In one example, when the method for producing 5'-guanine acid of the present application includes both a recovery step and a purification step, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of the order, or may be performed simultaneously or integrated into a single step, but is not limited thereto.
[0066] In the method of the present application, the strain and 5'-guanine acid, etc. are as described in the other embodiments above.
[0067]
[0068] Another aspect of the present application provides a composition for producing 5'-guanine acid, comprising the strain Corynebacterium ammoniagenes CJG0497 deposited under the accession number KCCM13320P of the present application; a culture of the strain, a fermentation product of the strain, or a combination of two or more thereof.
[0069] The composition of the present application may further comprise any suitable excipient commonly used in compositions for producing 5'-guanine acid, and such excipients may be, for example, but are not limited to, preservatives, wetting agents, dispersing agents, suspending agents, buffering agents, stabilizers, or isotonic agents.
[0070] In one specific example, each component present in the composition of the present application may be included in a bacteriologically effective amount, or in an amount that can be suitably present in the production composition.
[0071] In the composition of the present application, the strain and 5'-guanine acid, etc. are as described in the other embodiments above.
[0072]
[0073] Another aspect of the present application provides a use of the strain Corynebacterium ammoniagenes CJG0497, deposited under the accession number KCCM13320P of the present application, for producing 5'-guanine acid.
[0074] Another aspect of the present application provides a use for producing 5'-guanine acid using a composition comprising the strain Corynebacterium ammoniagenes CJG0497 deposited under accession number KCCM13320P; a culture of the strain, a fermentation product of the strain, or a combination of two or more thereof.
[0075] In the purpose of the present application, the strain and 5'-guanine acid, etc. are as described in the other aspects above.
[0076]
[0077] The present application will be described in more detail below through examples. However, the following examples are merely preferred embodiments intended to illustrate the present application and are therefore not intended to limit the scope of the present application. Furthermore, technical details not described herein can be readily understood and implemented by those skilled in the technical field of the present application or similar fields.
[0078]
[0079] Example 1: Selection of mutant strains using artificial mutagenesis
[0080]
[0081] To obtain a microbial mutant with GMP production ability, mutations were induced in the Corynebacterium ammoniagenes ATCC6872 strain.
[0082] The above Corynebacterium ammoniagenes ATCC6872 strain is currently called Corynebacterium stationenis ATCC6872 strain and is also used as Corynebacterium ammoniagenes ATCC6872.
[0083] Specifically, gamma-ray irradiation, a physical method, was applied to induce mutations. High-energy gamma rays emitted from the source Co-60 flow along the chromosome, randomly triggering changes in the base sequence, such as base substitutions, deletions, and insertions. Since the level of base sequence change is proportional to the gamma-ray irradiation intensity, high-level gamma rays induce mutations at a high rate while also increasing the killing rate of the strain. In order to sufficiently secure a high-quality, diverse mutant library with a high mutation rate, the gamma-ray irradiation conditions for the Corynebacterial strains that were the target of gamma-ray irradiation were first established. Using a high-level gamma irradiation device from Nordion located at the Advanced Radiation Research Institute of the Korea Atomic Energy Research Institute, 30 mL of seed medium culture with an absorbance value of 6.09 at 562 nm was irradiated with gamma rays at intensities of 0, 0.5, 1, 2, 3, 4, 5, and 7.5 10 kGy / hr for 1 hour, and then 10 kGy / hr was added to the seed medium. 0 , 10 -1 , 10 -2 , 10 -3 , 10 -4 Each 100-㎕ of the gamma-irradiated solution diluted at a dilution ratio of 100 kGy / hr was spread, and the plate medium on which the gamma-irradiated solution was spread was cultured in a 30℃ stationary incubator for 48 hours. The number of individual colonies formed was counted to calculate the killing rate for each irradiation condition. The CFU / mL according to the gamma-irradiation conditions of 0, 0.5, 1, 2, 3, 4, 5, and 7.5 10 kGy / hr was 3.6 X 10 8 , 6.9X10 7 , 9.8X10 6 , 2.7X10 5 , 2.1X10 3 , 3.0X10 1, 0, 0, 0, and the killing rates were 0, 81.00467, 97.31540, 99.92589, 99.99942, 99.99999, 100, 100, 100%, respectively. It was confirmed that the gamma-ray irradiation condition for securing a high-quality mutant library with high mutation diversity through gamma-ray irradiation based on Corynebacteria strains was 4-kGy / hr based on the above irradiation conditions.
[0084] To obtain a GMP high-conversion microorganism, a gamma-irradiation-based mutant library was constructed using the ATCC6872 strain, and GMP high-conversion mutants were screened. For gamma-irradiation of the ATCC6872 strain, a 500-mL flask containing 50 mL of seed medium was cultured in a shaking incubator at 30°C for 24 h to obtain a culture with an absorbance at 562 nm of 7.84. The culture was then diluted using the seed medium to an absorbance at 562 nm of 6.10. The 30-mL diluted solution was irradiated with 4 kGy / hr of gamma rays for 1 h using a high-level gamma-irradiation device at the Advanced Radiation Research Institute of the Korea Atomic Energy Research Institute, and 100 μL of the irradiation solution was spread onto each of 100 90 X 15 mm petri dishes. A total of 40,000 individual colonies were obtained by culturing the petri dishes in a 30°C incubator for 48 hours. To ensure the stability of the mutants, all individual colonies formed in all petri dishes were collected, suspended in a 20% glycerol solution, and then aliquoted into 1.5-mL microtubes (1 mL each) and stored in an ultra-low temperature freezer at -80°C. When screening for GMP high-conversion mutants, the 20% glycerol suspension taken out of the ultra-low temperature freezer and thawed at room temperature was diluted to 10 using saline. -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5After serial dilution, 100 μl of the diluted solution corresponding to each dilution factor was spread on the seed medium, and individual colonies were reactivated through 24 hours of culture in a 30℃ stationary incubator. The reactivated individual colonies were inoculated into a 96 Deep Well Plate, in which 350 μl of the seed medium corresponding to a filling rate of 17% was dispensed per well, using a Qpix420 Colony Picker facility from Molecular Devices. In the same plate, ATCC6872 strain that had not been irradiated with gamma rays was inoculated into 4 wells per plate to serve as a control for GMP high-conversion mutant screening. The 96 Deep Well Plates inoculated with the control strain and the mutants were sealed using Azenta's Gas permeable seal mark2 and cultured in a Multitron facility from Infors-HT at 30℃ and 1,000 rpm for 48 hours. After adding 1% xylene to the cultured strains and mutants and incubating for 1 hour, 150 μl of the titer evaluation solution containing XMP was added and incubated for 12 hours at 30°C and 1,000 rpm in a Multitron shaking incubator from Infors-HT. The 96 Deep Well Plate incubated for 12 hours was centrifuged for 20 minutes at 15°C and 4,000 rpm in a Centrifuge 5810R from Eppendorf. 100 μl of the culture supernatant from which the cells were separated was transferred to a 96 Well Black Polystyrene Microplate from Corning using a Biomek i5 liquid handler from Beckman Coulter for NIR Spectrometry analysis.Afterwards, the individual analysis spectrum of each well was obtained by applying it to the NIR Spectrometer manufactured in-house by the Analysis & Quality Department of CJ CheilJedang BIO Technology Research Institute, and the regression analysis prediction model with a coefficient of determination of 0.96 for the GMP concentration range of 0 to 20 g / L established based on the culture sample whose GMP concentration was quantified through prior HPLC analysis was applied, and the selection logic of 15% or more improvement in GMP concentration compared to the control group was applied, and 64 strains out of 11,451 mutants were initially selected. Cultivation was performed in the same way as above for the 64 selected strains, and the top 5 strains with high GMP concentrations were finally selected.
[0085]
[0086] The mutant strains obtained by the above method were named Corynebacterium ammoniagenes CJG0497, Corynebacterium ammoniagenes CJG0498, Corynebacterium ammoniagenes CJG0499, Corynebacterium ammoniagenes CJG0500, and Corynebacterium ammoniagenes CJG0501, respectively, and among them, the Corynebacterium ammoniagenes CJG0497 strain (Corynebacterium ammoniagenesCJG0497) was deposited with the Korea Microbiological Conservation Center, an international depository under the Budapest Treaty, on January 10, 2023 and assigned the accession number KCCM13320P.
[0087]
[0088] The composition of the medium used in Examples 1 and 2 is as follows.
[0089]
[0090] <Jongbaeji>
[0091] Glucose 30g / L, peptone 15g / L, yeast extract 15g / L, sodium chloride 2.5g / L, urea 3g / L, adenine 150mg / L, guanine 150mg / L, agar 20g / L, pH 7.0 (based on 1 liter of distilled water)
[0092]
[0093] <Valuation amount>
[0094] Trizma-base 24.20g / L, ATP 30g / L, XMPㆍ2Naㆍ7H2O 30g / L, magnesium sulfate 15g / L, ammonium sulfate 20g / L
[0095]
[0096] Example 2: Investigation of the ability of mutant strains for GMP production to convert XMP into GMP.
[0097]
[0098] In order to confirm the GMP conversion ability of Corynebacterium ammoniagenes CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501 obtained in Example 1 above to convert XMP into GMP, they were cultured using the following method.
[0099] The parent strain, Corynebacterium ammoniagenes ATCC6872, and the five mutant strains were each inoculated into a 250-ml corner-baffle flask containing 25 ml of seed medium, and cultured at 30°C for 20 hours with shaking at 200 rpm. 800 μl of the titer evaluation solution was added to 200 μl of the culture solution, and the mixture was reacted at 42°C for 30 minutes to produce GMP. After completion of the culture, the production amount of GMP was measured using liquid high-performance chromatography, and the GMP concentration in the culture solution for each strain tested is shown in Table 1 below.
[0100]
[0101] GMP conversion ability of Corynebacterium ammoniagenes ATCC6872, CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501 Comparative strain number XMP concentration (g / l) GMP concentration (g / l) Conversion rate (%) (GMP production amount / XMP consumption amount) ATCC6872 (parent strain) 9.06 0.58 6 1.7% CJG0497 (mutant strain 1) 5.63 3.45 7 8.9% CJG0498 (mutant strain 2) 7.48 1.69 6 7.1% CJG0499 (mutant strain 3) 6.08 2.8 4 7 2.4% CJG0500 (mutant strain 4) 6.44 2.5 8 7 2.5% CJG0501 (mutant strain 5) 6.03 2.8 1 7 0.8%
[0102] As a result, as shown in Table 1 above, the parent strain Corynebacterium ammoniagenes ATCC6872 produced (converted) GMP from XMP at a concentration of 0.58 g / l, but the mutant strains Corynebacterium ammoniagenes mutant strains CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501 of the present application were confirmed to convert GMP from XMP at concentrations of 3.45 g / l, 1.69 g / l, 2.84 g / l, 2.58 g / l, and 2.81 g / l, respectively.
[0103] That is, it was confirmed that the mutant strain Corynebacterium ammoniagenes CJG0497 of the present application had excellent GMP conversion ability and GMP production ability.
[0104]
[0105] Example 3: Investigation of GMP degradation of mutant strains for GMP production
[0106]
[0107] In order to confirm the GMP decomposition rate of Corynebacterium ammoniagenes CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501 obtained in Example 1, they were cultured using the following method.
[0108] The parent strain, Corynebacterium ammoniagenes ATCC6872, and the five mutant strains were each inoculated into a 250-ml corner-baffle flask containing 25 ml of seed medium, and cultured at 30°C for 20 hours with shaking at 200 rpm. 500 μl of GMP degradation evaluation medium was added to 500 μl of the culture solution, and the mixture was incubated at 30°C for 12 hours. The GMP concentration was measured using liquid high-performance chromatography, and the GMP concentration in the culture solution for each strain tested is shown in Table 2 below.
[0109]
[0110] Comparison of GMP degradation capacity of Corynebacterium ammoniagenes ATCC6872, CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501. Strain number. GMP concentration before reaction (g / l). GMP concentration after reaction (g / l). GMP Degradation amount (g / l) ATCC6872 (parent strain) 9.986.42 3.56 CJG0497 (mutant strain 1) 9.899.39 0.50 CJG0498 (mutant strain 2) 10.016.63 3.38 CJG0499 (mutant strain 3) 9.987.31 2.67 CJG0500 (mutant strain 4) 9.997.49 2.50 CJG0501 (mutant strain 5) 10.27.39 2.81
[0111] As a result, as shown in Table 2 above, the parent strain Corynebacterium ammoniagenes ATCC6872 decomposed 3.56 g / l GMP, but the mutant strains Corynebacterium ammoniagenes mutant strains CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501 according to the present invention were confirmed to decompose 0.50 g / l, 3.38 g / l, 2.67 g / l, 2.50 g / l, and 2.81 g / l of GMP, respectively.
[0112] That is, it was confirmed that the mutant strain Corynebacterium ammoniagenes CJG0497 of the present application can produce GMP with high efficiency and high yield by reducing the GMP decomposition rate compared to the parent strain.
[0113]
[0114] The composition of the medium used in Example 3 is as follows.
[0115]
[0116] <GMP 분해도평가 배지>
[0117] GMP 20g / L, phytic acid 1.8g / L, magnesium sulfate 4.8g / L, nymeen 3㎖ / L, xylene 2%, adenine 100mg / L, sodium hydrogen phosphate (Na2HPO4) 7.7g / L
[0118]
[0119] Example 4: Investigation of XMP degradation of mutant strains for GMP production
[0120]
[0121] In order to confirm the XMP decomposition degree of Corynebacterium ammoniagenes CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501 obtained in Example 1, they were cultured using the following method.
[0122] The parent strain Corynebacterium ammoniagenes ATCC6872 and the five mutant strains were each inoculated into a 250-ml corner-baffle flask containing 25 ml of seed medium, and then cultured at 30°C for 20 hours with shaking at 200 rpm. 500 μl of the XMP degradation evaluation medium was added to 500 μl of the culture solution, and the mixture was incubated at 30°C for 12 hours. The XMP concentration was measured using liquid high-performance chromatography, and the XMP concentration in the culture solution for each strain tested is shown in Table 3 below.
[0123]
[0124] Comparison of XMP degradation capacity of Corynebacterium ammoniagenes ATCC6872, CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501. Strain number. XMP concentration before reaction (g / l). XMP concentration after reaction (g / l). XMP Degradation amount (g / l) ATCC6872 (parent strain) 10.05 7.52 2.53 CJG0497 (mutant strain 1) 9.98 8.39 1.59 CJG0498 (mutant strain 2) 10.017 71 2.30 CJG0499 (mutant strain 3) 10.017 94 2.07 CJG0500 (mutant strain 4) 9.95 8.07 1.88 CJG0501 (mutant strain 5) 9.99 7.79 2.20
[0125] As a result, as shown in Table 3 above, the parent strain Corynebacterium ammoniagenes ATCC6872 decomposed 2.53 g / l XMP, but the mutant strains Corynebacterium ammoniagenes mutant strains CJG0497, CJG0498, CJG0499, CJG0500, and CJG0501 according to the present invention were confirmed to decompose 1.59 g / l, 2.30 g / l, 2.07 g / l, 1.88 g / l, and 2.20 g / l of XMP, respectively.
[0126] That is, it was confirmed that the mutant strain Corynebacterium ammoniagenes CJG0497 of the present application can produce GMP with high efficiency and high yield by reducing the XMP decomposition rate compared to the parent strain.
[0127]
[0128] The composition of the medium used in Example 4 is as follows.
[0129]
[0130] <XMP 분해도평가 배지>
[0131] XMP 20g / L, phytic acid 1.8g / L, magnesium sulfate 4.8g / L, nymeen 3㎖ / L, xylene 2%, adenine 100mg / L, sodium hydrogen phosphate (Na2HPO4) 7.7g / L
[0132]
[0133] Example 5: Genetic analysis of mutant strains for GMP production
[0134]
[0135] In order to analyze the genetic differences of the Corynebacterium ammoniagenes CJG0497 strain obtained in Example 1, a genome comparison analysis experiment was conducted with the Corynebacterium ammoniagenes wild strain ATCC6872.
[0136]
[0137] Specifically, for extraction of genomic DNA (gDNA) for next-generation sequencing (NGS), Corynebacterium ammoniagenes CJG0497 and ATCC6872 strains, which had been plated on optimal culture medium and cultured for at least 24 hours, were used. The cells obtained using a 10-μL loop (SPL inc., Cat. No: 90010) were suspended in 300-μL of PBS. After stirring, 175-μL of the strain suspension was taken, mixed with Lysis / Binding Solution (232-μL Lysis / Binding Solution Concentrate and 3-μL Carrier NA; a component of the MagMaxTM Total Nucleic Acid Isolation Kit), and lysed twice in a bead tube at 6500 rpm for 1 min. Subsequent procedures were performed using the MagMax™ Total Nucleic Acid Isolation Kit (Thermo Fisher Scientific Inc., Cat. No. AM1840) according to the manufacturer's recommendations. The gDNA obtained from this kit was quantitatively analyzed using a Qubit Fluorometer (Thermo Fisher Scientific Inc.).
[0138] The gDNA of the strains obtained for long-read sequencing was diluted to 1500-ng gDNA / 48-μL DW, and then the Ligation Sequencing Kit (Oxford Nanopore Technologies Inc., Cat. No: SQK-LSK109) and the Native Barcoding Expansion 1-12 (PCR-free) Kit (Oxford Nanopore Technologies Inc., Cat. No: EXP-NBD104) were used, and the sequencing library was prepared by performing the processes of nick and gap filling, dA tailing and barcoding, and adapter ligation according to the manufacturer's recommended method. The prepared library sample was subjected to sequence analysis for approximately 24 hours using the MinION Mk1C device (Oxford Nanopore Technologies Inc.).
[0139] The gDNA of the strains obtained for short-read sequencing was diluted to 100-ng gDNA / 50-μL DW, and DNA shearing and barcoding were performed according to the manufacturer's recommended methods using the Ion Plus Fragment Library Kit for Library Builder™ (Thermo Fisher Scientific Inc., Cat. No: 4477597), Ion Xpress™ Plus Fragment Library (Thermo Fisher Scientific Inc., Cat. No: 4477597), and AB Library Builder™ equipment (Thermo Fisher Scientific Inc.). Similarly, adapter ligation, nick-repair, and library amplification were also performed according to the manufacturer's recommended methods. The final sequencing library obtained from this was diluted to a final concentration of 50 pM and used in Ion 510 TM & Ion 520 TM & Ion 530 TM Emulsion PCR and enrichment were performed using Kit - Chef (Thermo Fisher Scientific Inc., Cat. No: A34461) and Ion Chef System equipment (Thermo Fisher Scientific Inc.), and finally Ion 530 TM Chip (Ion 530 TMChip Kit, Thermo Fisher Scientific Inc., Cat. No: A27764) and sequence analysis was performed. After sequence analysis, adapter sequence removal and quality check were performed through a torrent server, and whole-genome assembly and polishing were performed using the raw sequence data (raw fastq data) obtained from this.
[0140]
[0141] Comparative analysis of gene sequence differences between Corynebacterium ammoniagenes ATCC6872 and CJG0497. Gene, Protein, ATCC6872, CJG0497. Nucleotide, Peptide, Nucleotide, Peptide, hrpB, hypothetical protein, G979P327A979S327sra. Phypothetical protein, G263S88A263F88.
[0142] Comparative analysis of non-coding region sequence differences between Corynebacterium ammoniagenes ATCC6872 and CJG0497 Type Location Location Information Nucleotide ATCC6872 CJG0497 rRNA1546059 ORF Name: rrna02GA rRNA1546191 ORF Name: rrna02AG
[0143] As a result, as shown in Table 4 above, it was confirmed that non-synonymous mutations in two genes (hrpB (P327S), sraP (S88F)) were observed in the mutant strain Corynebacterium ammoniagenes CJG0497 of the present application compared to the parent strain Corynebacterium ammoniagenes ATCC6872.
[0144] In addition, as shown in Table 5 above, it was confirmed that nucleotide mutations were observed at two rRNA ORF positions in the mutant strain Corynebacterium ammoniagenes CJG0497 of the present application compared to the parent strain Corynebacterium ammoniagenes ATCC6872.
[0145] That is, it was confirmed that the Corynebacterium ammoniagenes mutant strain of the present application has genetic differences from the parent strain.
[0146]
[0147] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.
[0148]
[0149]
Claims
1. Corynebacterium ammoniagenes CJG0497 strain deposited under accession number KCCM13320P.
2. A strain according to claim 1, wherein the strain has the ability to produce 5'-guanine acid.
3. A strain according to claim 1, wherein the strain has a converting ability to convert 5'-xanthrylic acid into 5'-guanine acid.
4. A method for producing 5'-guanine acid, comprising a step of culturing the Corynebacterium ammoniagenes CJG0497 strain deposited under accession number KCCM13320P in a medium.
5. A method according to claim 4, further comprising a step of recovering 5'-guanine acid from the cultured strain, a culture of the strain, a fermented product of the strain, or the culture medium.
6. A composition for producing 5'-guanine acid comprising the strain Corynebacterium ammoniagenes CJG0497 deposited under accession number KCCM13320P, a culture of the strain, a fermented product of the strain, or a combination of two or more thereof.
7. Use of the Corynebacterium ammoniagenes CJG0497 strain deposited under accession number KCCM13320P for 5'-guanine acid production.
